Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab Plus Platinum Chemotherapy as Adjuvant Therapy in Stage IIA–IIIA NSCLC
ChiCTR2100053236Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Disease-free survival (DFS) rate. Started Nov 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100053236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053236.